✦ LIBER ✦

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?

✍ Scribed by Hale, G; Slavin, S; Goldman, J M; Mackinnon, S; Giralt, S; Waldmann, H

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Alemtuzumab (Campath-1H) in the treatmen

✍ Alinari, L; Lapalombella, R; Andritsos, L; Baiocchi, R A; Lin, T S; Byrd, J C 📂 Article 📅 2007 🏛 Nature Publishing Group 🌐 English ⚖ 146 KB

The evolving role of alemtuzumab (Campat

✍ Joseph F. Magliocca; Stuart J. Knechtle 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 486 KB

Subcutaneous alemtuzumab vs ATG in adjus

✍ Juliusson, G; Theorin, N; Karlsson, K; Frödin, U; Malm, C 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 189 KB

A novel conditioning regimen of immune s

✍ Y. Barnes; R. Hayashi; L. Yu; J. DiPersio; W. Grossman; S. Witty; M. Heigham; K. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 74 KB

Campath-1H as Rescue Therapy for the Tre

✍ Z. Csapo; C. Benavides-Viveros; H. Podder; V. Pollard; B.D. Kahan 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 138 KB

Campath-1H (Alemtuzumab) as an Induction

✍ A.S. Muñoz; C.B. Cabanayan-Casasola; R.A. Danguilan; F.B. Padua; E.T. Ona 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 101 KB